ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

UCB buying Ra Pharmaceuticals for $2.1 billion

by Rick Mullin
October 19, 2019 | APPEARED IN VOLUME 97, ISSUE 41

 

Acting to bolster its drug pipeline for myasthenia gravis, UCB has agreed to buy Ra Pharmaceuticals in a deal valued at $2.1 billion. The acquisition will place Ra’s zilucoplan, a peptide in Phase III clinical trials to treat the neuromuscular disease, beside UCB’s rozanolixizumab, an antibody also in Phase III trials against the disease. UCB will also net Ra’s Extreme Diversity technology for producing synthetic macrocyclic peptides. UCB plans to keep Ra’s Cambridge, Massachusetts, research center in place.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment